A multifunctional peptide rescues memory deficits in Alzheimer's disease transgenic mice by inhibiting Aβ42-induced cytotoxicity and increasing microglial phagocytosis

Neurobiology of Disease

Volumn 46, Issue 3, 2012, Pages 701-709

  Xue, Di ^a,b   Zhao, Min ^a   Wang, Yu Jiong ^b   Wang, Li ^a   Yang, Yang ^a,b   Wang, Shao Wei ^a   Zhang, Ran ^a,b   Zhao, Yang ^c   Liu, Rui Tian ^a  

^a Tsinghua University   (China)

^b NINGXIA UNIVERSITY   (China)

^c NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

Author keywords

Amyloid; A clearance; Alzheimer's disease; Cytotoxicity; Memory deficits; Peptide

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; HEPTAPEPTIDE; NITRIC OXIDE; PRESENILIN 1; PROPYLISOLEUCYLLYSYLTHREONYLLEUCYLPROPYLMETHIONINE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM HOMEOSTASIS; CELL PHAGOCYTOSIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BLOTTING, WESTERN; CALCIUM; CELL LINE, TUMOR; CELL SURVIVAL; CLONING, MOLECULAR; COLORING AGENTS; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; MICROGLIA; NITRIC OXIDE; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; PEPTIDES; PHAGOCYTOSIS; REACTIVE OXYGEN SPECIES; TETRAZOLIUM SALTS; THIAZOLES;

EID: 84860833660     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.03.013     Document Type: Article

References (74)

1. Adessi C., Frossard M.J., Boissard C., Fraga S., Bieler S., Ruckle T., Vilbois F., Robinson S.M., Mutter M., Banks W.A., Soto C. Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J. Biol. Chem. 2003, 278:13905-13911.
2. Azzazy H.M., Highsmith W.E. Phage display technology: clinical applications and recent innovations. Clin. Biochem. 2002, 35:425-445.
3. Bao F., Wicklund L., Lacor P.N., Klein W.L., Nordberg A., Marutle A. Different beta-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol. Aging 2002, 33:825.e1-825.e13.
4. Barghorn S., Nimmrich V., Striebinger A., Krantz C., Keller P., Janson B., Bahr M., Schmidt M., Bitner R.S., Harlan J., Barlow E., Ebert U., Hillen H. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J. Neurochem. 2005, 95:834-847.
5. Becker R.E., Greig N.H. Alzheimer's disease drug development: old problems require new priorities. CNS Neurol. Disord. Drug Targets 2008, 7:499-511.
6. Becker R.E., Greig N.H., Giacobini E. Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?. J. Alzheimers Dis. 2008, 15:303-325.
7. Bruce N.J., Chen D., Dastidar S.G., Marks G.E., Schein C.H., Bryce R.A. Molecular dynamics simulations of Abeta fibril interactions with beta-sheet breaker peptides. Peptides 2010, 31:2100-2108.
8. Butterfield D.A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 2001, 7:548-554.
9. Chen J., Armstrong A.H., Koehler A.N., Hecht M.H. Small molecule microarrays enable the discovery of compounds that bind the Alzheimer's Abeta peptide and reduce its cytotoxicity. J. Am. Chem. Soc. 2010, 132:17015-17022.
10. Chini M.G., Scrima M., D'Ursi A.M., Bifulco G. Fibril aggregation inhibitory activity of the beta-sheet breaker peptides: a molecular docking approach. J. Pept. Sci. 2009, 15:229-234.
11. Coraci I.S., Husemann J., Berman J.W., Hulette C., Dufour J.H., Campanella G.K., Luster A.D., Silverstein S.C., El-Khoury J.B. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am. J. Pathol. 2002, 160:101-112.
12. Dimakopoulos A.C. Protein aggregation in Alzheimer's disease and other neuropathological disorders. Curr. Alzheimer Res. 2005, 2:19-28.
13. Doig A.J. Peptide inhibitors of beta-amyloid aggregation. Curr. Opin. Drug Discov. Devel. 2007, 10:533-539.
14. Estrada L.D., Soto C. Disrupting beta-amyloid aggregation for Alzheimer disease treatment. Curr. Top. Med. Chem. 2007, 7:115-126.
15. El Khoury J., Hickman S.E., Thomas C.A., Cao L., Silverstein S.C., Loike J.D. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 1996, 382:716-719.
16. Esteras-Chopo A., Pastor M.T., Serrano L., Lopez de la Paz M. New strategy for the generation of specific D-peptide amyloid inhibitors. J. Mol. Biol. 2008, 377:1372-1381.
17. Feng Y., Wang X.P., Yang S.G., Wang Y.J., Zhang X., Du X.T., Sun X.X., Zhao M., Huang L., Liu R.T. Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation. Neurotoxicology 2009, 30:986-995.
18. Finder V.H., Glockshuber R. Amyloid-beta aggregation. Neurodegener Dis 2007, 4:13-27.
19. Fradinger E.A., Monien B.H., Urbanc B., Lomakin A., Tan M., Li H., Spring S.M., Condron M.M., Cruz L., Xie C.W., Benedek G.B., Bitan G. C-terminal peptides coassemble into Abeta42 oligomers and protect neurons against Abeta42-induced neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14175-14180.
20. Fuhrmann M., Bittner T., Jung C.K., Burgold S., Page R.M., Mitteregger G., Haass C., LaFerla F.M., Kretzschmar H., Herms J. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat. Neurosci. 2010, 13:411-413.
21. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. 2007, 8:101-112.
22. Haley T.J., McCormick W.G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br. J. Pharmacol. Chemother. 1957, 12:12-15.
23. Handattu S.P., Garber D.W., Monroe C.E., van Groen T., Kadish I., Nayyar G., Cao D., Palgunachari M.N., Li L., Anantharamaiah G.M. Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. Neurobiol. Dis. 2009, 34:525-534.
24. Hatip F.F., Suenaga M., Yamada T., Matsunaga Y. Reversal of temperature-induced conformational changes in the amyloid-beta peptide, Abeta40, by the beta-sheet breaker peptides 16-23 and 17-24. Br. J. Pharmacol. 2009, 158:1165-1172.
25. Hetenyi C., Kortvelyesi T., Penke B. Mapping of possible binding sequences of two beta-sheet breaker peptides on beta amyloid peptide of Alzheimer's disease. Bioorg. Med. Chem. 2002, 10:1587-1593.
26. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C.M., Eckman C., Younkin S., Hsiao K., Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 1998, 4:97-100.
27. Hong H.S., Rana S., Barrigan L., Shi A., Zhang Y., Zhou F., Jin L.W., Hua D.H. Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo. J. Neurochem. 2009, 108:1097-1108.
28. Hoos M.D., Ahmed M., Smith S.O., Van Nostrand W.E. Inhibition of familial cerebral amyloid angiopathy mutant amyloid beta-protein fibril assembly by myelin basic protein. J. Biol. Chem. 2007, 282:9952-9961.
29. Hughes E., Burke R.M., Doig A.J. Inhibition of toxicity in the beta-amyloid peptide fragment beta-(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation. J. Biol. Chem. 2000, 275:25109-25115.
30. Husemann J., Loike J.D., Anankov R., Febbraio M., Silverstein S.C. Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system. Glia 2002, 40:195-205.
31. Janusz M., Woszczyna M., Lisowski M., Kubis A., Macala J., Gotszalk T., Lisowski J. Ovine colostrum nanopeptide affects amyloid beta aggregation. FEBS Lett. 2009, 583:190-196.
32. Jiang D., Li X., Williams R., Patel S., Men L., Wang Y., Zhou F. Ternary complexes of iron, amyloid-beta, and nitrilotriacetic acid: binding affinities, redox properties, and relevance to iron-induced oxidative stress in Alzheimer's disease. Biochemistry 2009, 48:7939-7947.
33. Jin M., Shepardson N., Yang T., Chen G., Walsh D., Selkoe D.J. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:5819-5824.
34. Karran E., Mercken M., Strooper B.D. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 2011, 10:698-712.
35. Kawahara M., Kuroda Y. Molecular mechanism of neurodegeneration induced by Alzheimer's beta-amyloid protein: channel formation and disruption of calcium homeostasis. Brain Res. Bull. 2000, 53:389-397.
36. Kawasaki T., Onodera K., Kamijo S. Identification of novel short peptide inhibitors of soluble 37/48kDa oligomers of amyloid beta42. Biosci. Biotechnol. Biochem. 2011, 75:1496-1501.
37. Klafki H.W., Staufenbiel M., Kornhuber J., Wiltfang J. Therapeutic approaches to Alzheimer's disease. Brain 2006, 129:2840-2855.
38. Klementiev B., Novikova T., Novitskaya V., Walmod P.S., Dmytriyeva O., Pakkenberg B., Berezin V., Bock E. A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25-35. Neuroscience 2007, 145:209-224.
39. Kwak J.W., Kim H.K., Chae C.B. Potential lead for an Alzheimer drug: a peptide that blocks intermolecular interaction and amyloid beta protein-induced cytotoxicity. J. Med. Chem. 2006, 49:4813-4817.
40. Larbanoix L., Burtea C., Laurent S., Van Leuven F., Toubeau G., Vander Elst L., Muller R.N. Potential amyloid plaque-specific peptides for the diagnosis of Alzheimer's disease. Neurobiol. Aging 2010, 31:1679-1689.
41. Liu R., Barkhordarian H., Emadi S., Park C.B., Sierks M.R. Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiol. Dis. 2005, 20:74-81.
42. Liu R., Yuan B., Emadi S., Zameer A., Schulz P., McAllister C., Lyubchenko Y., Goud G., Sierks M.R. Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry 2004, 43:6959-6967.
43. Longo F.M., Massa S.M. Neuroprotective strategies in Alzheimer's disease. NeuroRx 2004, 1:117-127.
44. Maezawa I., Zimin P.I., Wulff H., Jin L.W. Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J. Biol. Chem. 2011, 286:3693-3706.
45. Magdesian M.H., Nery A.A., Martins A.H., Juliano M.A., Juliano L., Ulrich H., Ferreira S.T. Peptide blockers of the inhibition of neuronal nicotinic acetylcholine receptors by amyloid beta. J. Biol. Chem. 2005, 280:31085-31090.
46. Mason J.M., Kokkoni N., Stott K., Doig A.J. Design strategies for anti-amyloid agents. Curr. Opin. Struct. Biol. 2003, 13:526-532.
47. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
48. McLaurin J., Kierstead M.E., Brown M.E., Hawkes C.A., Lambermon M.H., Phinney A.L., Darabie A.A., Cousins J.E., French J.E., Lan M.F., Chen F., Wong S.S., Mount H.T., Fraser P.E., Westaway D.St, George-Hyslop P. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 2006, 12:801-808.
49. Muller W.E., Koch S., Eckert A., Hartmann H., Scheuer K. beta-Amyloid peptide decreases membrane fluidity. Brain Res. 1995, 674:133-136.
50. Noguchi A., Matsumura S., Dezawa M., Tada M., Yanazawa M., Ito A., Akioka M., Kikuchi S., Sato M., Ideno S., Noda M., Fukunari A., Muramatsu S., Itokazu Y., Sato K., Takahashi H., Teplow D.B., Nabeshima Y., Kakita A., Imahori K., Hoshi M. Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. J. Biol. Chem. 2009, 284:32895-32905.
51. Ono K., Yoshiike Y., Takashima A., Hasegawa K., Naiki H., Yamada M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J. Neurochem. 2003, 87:172-181.
52. Orner B.P., Liu L., Murphy R.M., Kiessling L.L. Phage display affords peptides that modulate beta-amyloid aggregation. J. Am. Chem. Soc. 2006, 128:11882-11889.
53. Permanne B., Adessi C., Saborio G.P., Fraga S., Frossard M.J., Van Dorpe J., Dewachter I., Banks W.A., Van Leuven F., Soto C. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J. 2002, 16:860-862.
54. Rosini M., Andrisano V., Bartolini M., Bolognesi M.L., Hrelia P., Minarini A., Tarozzi A., Melchiorre C. Rational approach to discover multipotent anti-Alzheimer drugs. J. Med. Chem. 2005, 48:360-363.
55. Savonenko A., Xu G.M., Melnikova T., Morton J.L., Gonzales V., Wong M.P., Price D.L., Tang F., Markowska A.L., Borchelt D.R. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol. Dis. 2005, 18:602-617.
56. Schiefer I.T., Abdul-Hay S., Wang H., Vanni M., Qin Z., Thatcher G.R. Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates. J. Med. Chem. 2011, 54:2293-2306.
57. Shankar G.M., Leissring M.A., Adame A., Sun X., Spooner E., Masliah E., Selkoe D.J., Lemere C.A., Walsh D.M. Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol. Dis. 2009, 36:293-302.
58. Sievers S.A., Karanicolas J., Chang H.W., Zhao A., Jiang L., Zirafi O., Stevens J.T., Munch J., Baker D., Eisenberg D. Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature 2011, 475:96-100.
59. Smith G.P., Petrenko V.A. Phage Display. Chem. Rev. 1997, 97:391-410.
60. Stockley J.H., O'Neill C. The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain. Biochem. Soc. Trans. 2007, 35:574-576.
61. Sun X., Wu W.H., Liu Q., Chen M.S., Yu Y.P., Ma Y., Zhao Y.F., Li Y.M. Hybrid peptides attenuate cytotoxicity of beta-amyloid by inhibiting its oligomerization: implication from solvent effects. Peptides 2009, 30:1282-1287.
62. Szegedi V., Juhasz G., Rozsa E., Juhasz-Vedres G., Datki Z., Fulop L., Bozso Z., Lakatos A., Laczko I., Farkas T., Kis Z., Toth G., Soos K., Zarandi M., Budai D., Toldi J., Penke B. Endomorphin-2, an endogenous tetrapeptide, protects against Abeta1-42 in vitro and in vivo. FASEB J. 2006, 20:1191-1193.
63. Taddei K., Laws S.M., Verdile G., Munns S., D'Costa K., Harvey A.R., Martins I.J., Hill F., Levy E., Shaw J.E., Martins R.N. Novel phage peptides attenuate beta amyloid-42 catalysed hydrogen peroxide production and associated neurotoxicity. Neurobiol. Aging 2010, 31:203-214.
64. Tahara K., Kim H.D., Jin J.J., Maxwell J.A., Li L., Fukuchi K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain 2006, 129:3006-3019.
65. Thapa A., Woo E.R., Chi E.Y., Sharoar M.G., Jin H.G., Shin S.Y., Park I.S. Biflavonoids are superior to monoflavonoids in inhibiting amyloid-beta toxicity and fibrillogenesis via accumulation of nontoxic oligomer-like structures. Biochemistry 2011, 50:2445-2455.
66. Thomas T., Bryant M., Clark L., Garces A., Rhodin J. Estrogen and raloxifene activities on amyloid-beta-induced inflammatory reaction. Microvasc. Res. 2001, 61:28-39.
67. Thomas T., Nadackal T.G., Thomas K. Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation. Neuroreport 2001, 12:3263-3267.
68. Townsend M. When will Alzheimer's disease be cured? A pharmaceutical perspective. J. Alzheimers Dis. 2011, 24(Suppl. 2):43-52.
69. Vorhees C.V., Williams M.T. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 2006, 1:848-858.
70. Wang X.P., Zhang J.H., Wang Y.J., Feng Y., Zhang X., Sun X.X., Li J.L., Du X.T., Lambert M.P., Yang S.G., Zhao M., Klein W.L., Liu R.T. Conformation-dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers. FEBS Lett. 2009, 583:579-584.
71. Wei C.W., Peng Y., Zhang L., Huang Q., Cheng M., Liu Y.N., Li J. Synthesis and evaluation of ferrocenoyl pentapeptide (Fc-KLVFF) as an inhibitor of Alzheimer's Abeta(1-42) fibril formation in vitro. Bioorg. Med. Chem. Lett. 2011, 21:5818-5821.
72. Yang C.N., Shiao Y.J., Shie F.S., Guo B.S., Chen P.H., Cho C.Y., Chen Y.J., Huang F.L., Tsay H.J. Mechanism mediating oligomeric Abeta clearance by naive primary microglia. Neurobiol. Dis. 2011, 42:221-230.
73. Yang S.G., Wang W.Y., Ling T.J., Feng Y., Du X.T., Zhang X., Sun X.X., Zhao M., Xue D., Yang Y., Liu R.T. Alpha-tocopherol quinone inhibits beta-amyloid aggregation and cytotoxicity, disaggregates preformed fibrils and decreases the production of reactive oxygen species, NO and inflammatory cytokines. Neurochem. Int. 2010, 57:914-922.
74. Yang S.G., Zhang X., Sun X.S., Ling T.J., Feng Y., Du X.Y., Zhao M., Yang Y., Xue D., Wang L., Liu R.T. Diverse ecdysterones show different effects on amyloid-beta42 aggregation but all uniformly inhibit amyloid-beta42-induced cytotoxicity. J. Alzheimers Dis. 2010, 22:107-117.